How Medtech and Surgical Robotics Founders Should Approach Growth Capital

Most founders open a medtech investment conversation with clinical results and the size of the market. Growth-stage investors usually want two narrower answers first: which FDA pathway takes the device to market, and who pays for each procedure once it gets there. A company that can answer both with dates and payment logic has a capital story. A company that cannot is still telling a science story, and investors price that as venture risk.

Capital for the category exists. Bain estimates that medtech deal value in healthcare private equity nearly doubled in 2025 to about $33 billion, across an estimated 88 deals. It goes to companies that have mapped the route from authorization to reimbursed use.

01Why medtech investment runs on a different clock than biopharma

A drug program concentrates most of its value in one regulatory event after years of trials. Device programs move differently. Many devices reach the market through a 510(k), which shows the device is substantially equivalent to a legally marketed predicate, and FDA says that determination is usually made within 90 days. Novel devices with no predicate can request De Novo classification, and a device classified into class I or II that way can serve as the predicate for later 510(k) submissions. Class III devices need premarket approval (PMA), which requires sufficient valid scientific evidence to assure that the device is safe and effective for its intended use.

Shorter review cycles let device companies iterate faster, but authorization is where commercial risk begins, not where it ends. After clearance or approval, revenue still depends on a hospital value-analysis committee, a surgeon willing to change technique, and a payment that covers the cost of the case. The practical difference for medical device funding is that investors underwrite the months between authorization and a repeatable purchase order, not only the probability of authorization. Diagnostics companies face a version of the same gap between clearance and coverage, and it shapes much of the precision medicine investment landscape.

02The reimbursement question investors will ask first

A credible medical device reimbursement strategy separates three questions that founders tend to blend together: coding, coverage and payment. A code describes the service on a claim. Coverage decides whether a payer will pay for it at all. Payment sets the amount. CMS is blunt about the gap: assignment of a new code does not automatically imply coverage by any payer. For new procedures, the AMA maintains CPT Category III, a temporary set of codes for emerging technologies, services and procedures, which describes a procedure without settling what anyone pays.

For hospital outpatient procedures, Medicare pays through the Hospital Outpatient Prospective Payment System, where all items and services are assigned to Ambulatory Payment Classifications that group services that are similar clinically and in resource use. Under the comprehensive APC policy, many supporting items are paid as part of a primary service. That packaging is the core problem for a new device: if it costs more than the payment group assumes, every case can lose the hospital money.

Transitional pass-through status is the bridge. Devices approved for it are eligible for pass-through payment for at least two but not more than three years, and CMS evaluates applications quarterly. It is not a formality. A study in JAMA Health Forum found that between 2017 and 2023, CMS awarded pass-through payment for 17 of 43 applications, and 19 of the 26 denials were for not demonstrating substantial clinical improvement in Medicare beneficiaries. Applications through the alternative pathway for FDA Breakthrough Devices, which does not require that showing, went 8 for 8. Inpatient procedures have a parallel mechanism, the new technology add-on payment, limited to the lesser of 65% of the costs of the technology or 65% of the amount by which the costs of the case exceed the standard MS-DRG payment. The application deadline for fiscal year 2028 is October 5, 2026.

The decision rule: before the clinical story, a founder should be able to say which code describes the procedure today, which payer decision covers it, what the hospital is paid per case, and what share of that payment the device consumes. If any answer is still open, the plan and the budget for closing it belong in the raise.

03FDA pathways that change your capital story

The FDA Breakthrough Devices Program is a voluntary program for devices that provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. A device must also meet one of four further tests, such as representing breakthrough technology or having no approved or cleared alternative. Designated devices can request sprint discussions, a discussion of the data development plan and clinical protocol agreement, and they receive prioritized review of later submissions. The submission itself still goes through 510(k), De Novo or PMA review.

Designation is a head start, not an outcome. As of June 30, 2026, FDA reported 1,320 Breakthrough Device designations and 210 marketing authorizations for an indication consistent with the designation. Investors read a designation as evidence that FDA accepts the unmet need, then diligence the clinical plan as rigorously as they would without it.

Its larger value now sits on the payment side. It is also the entry ticket to Medicare's accelerated coverage processes. CMS finalized Transitional Coverage for Emerging Technologies (TCET) in 2024, with a goal of finalizing a national coverage determination within six months of FDA market authorization for up to five candidates a year. In April 2026, FDA and CMS announced the RAPID coverage pathway for certain Class II Breakthrough Devices enrolled in FDA's Total Product Life Cycle Advisory Program and Class III Breakthrough Devices. Under CMS's procedural notice, a proposed national coverage determination is issued the same day as FDA market authorization, with a final decision targeted about 60 days later for Class II devices and 90 days later for Class III devices. In vitro diagnostic products are excluded, and TCET is paused for new candidates while CMS implements RAPID. The notice invited public comment, so details can still change.

The timing is what matters for a capital plan. RAPID is open to devices at the IDE pre-submission stage, and CMS says devices beyond that stage are not appropriate for it. Medicare-relevant outcomes therefore have to be built into the pivotal study before it starts, so reimbursement planning now comes before study design. A company one quarter from filing its IDE that has not engaged CMS may be about to give up the fastest coverage route available to it. Software-driven and AI-enabled devices add their own layer of FDA expectations, which a separate piece on FDA digital health guidance covers.

04What growth-stage investors actually diligence

Beyond the science, diligence reduces to three questions, each with a number attached.

• Unit economics per procedure. What the hospital is paid for the case, what the device and its disposables cost, and what margin is left for the hospital and the company.
• The adoption curve. Trained surgeons, procedures per site per month, time from first case to steady use, and how many sites keep ordering after year one.
• The code. Whether the procedure already bills under an existing code with adequate payment, or whether the company must create a code, win coverage and apply for transitional payment.

The category leader's results show why investors weight adoption so heavily. Intuitive, maker of the da Vinci system, reported total 2025 revenue of $10.1 billion, a company-wide figure rather than a measure of the surgical robotics market. Systems revenue was $2.47 billion of that, while instruments and accessories alone brought in $6.02 billion and service another $1.57 billion. About 3,153,000 da Vinci procedures were performed in 2025, up 18%, on an installed base of roughly 11,106 systems, and procedures per system rose 3%. The lesson for a newer platform: placements are the cost of entry, and the business is recurring revenue per procedure. Investors model utilization per installed system and discount placement pipelines not backed by surgeon training capacity.

The same logic governs medical device startup funding: capital follows evidence that a product is used repeatedly, is paid for, and earns a margin on each use. One strong launch site proves the product works. Ten sites with rising utilization prove the business works.

05Positioning your company for growth capital

Sequence the raise around the events that remove the largest remaining uncertainty, not around a calendar date. For most device companies the order is predictable:

1. Breakthrough designation, if the device qualifies, and early engagement with CMS where RAPID applies.
2. An IDE and pivotal study that measure the outcomes payers will ask about.
3. FDA clearance, De Novo grant or PMA approval.
4. A coverage decision and a payment path: an existing code with adequate payment, a pass-through or add-on payment approval, or a national coverage determination.
5. Repeatable use at a growing number of sites.

Growth equity usually fits after steps three and four, when the question shifts from whether the device works to how fast the company can scale it. Raising just before a milestone forces investors to price the risk that milestone would remove. Raising just after it lets the company sell a result.

Size the round to reach the next milestone with room for payment lag. Pass-through applications move on quarterly cycles, add-on payment applications follow an annual deadline, and hospital purchasing committees add months of their own. Build the reporting that lets an investor verify all of it quickly: procedure volumes by site, reimbursement status by payer, and cost per case. That operational infrastructure is part of the fundraising story, and in medtech it often decides how the round is priced.

06Frequently asked questions

How is medical device funding different from biopharma funding?

Biopharma value tends to concentrate in a single approval after long clinical trials. Many devices reach the market faster, often through a 510(k) that FDA usually decides within 90 days, but authorization starts the commercial risk rather than ending it. Device revenue depends on hospital purchasing, surgeon adoption, coding, coverage and payment per procedure, so investors underwrite the time from authorization to repeatable, reimbursed use.

What is the FDA Breakthrough Devices Program?

It is a voluntary FDA program for devices that provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating conditions and meet one further test, such as representing breakthrough technology or having no cleared or approved alternative. Designated devices get interactive feedback options and prioritized review, but still go through 510(k), De Novo or PMA review. As of June 30, 2026, FDA reported 1,320 designations.

How does Medicare reimbursement affect a medtech startup's fundability?

Reimbursement sets how quickly authorization turns into revenue. Investors check whether a code exists, whether Medicare covers the procedure, and whether the hospital's payment covers the device's cost. New outpatient devices can seek transitional pass-through payment for two to three years, and inpatient technologies can seek new technology add-on payments. Without a clear reimbursement plan, a company is usually priced as earlier-stage risk.

What do growth equity investors look for in a surgical robotics company?

They look past clearance to per-procedure economics: what the hospital is paid for the case, the cost of instruments and service, and the margin left over. They track procedures per installed system, surgeon training capacity, and whether reimbursement exists for the procedures the system performs. Recurring revenue matters most; Intuitive's 2025 instruments and accessories revenue was more than double its systems revenue.

When should a medtech company raise growth capital versus venture capital?

Growth capital typically fits once a device has cleared its main regulatory hurdle, has a defined coverage and payment path, and shows early repeat use at several sites. At that point the company needs money to scale manufacturing, sales, training and reimbursement support rather than to prove the product works. Rounds that fund core development and pivotal trials are usually venture capital.

Nothing in this piece is investment, legal, tax or accounting advice, and nothing in it is an offer to sell or a solicitation of an offer to buy any security.